Utah Medical Products, Inc. (NASDAQ:UTMD) is a leading manufacturer and marketer of specialty medical devices, with a particular focus on healthcare solutions for women and their babies. Despite facing headwinds in certain key revenue streams, the company has demonstrated its ability to maintain robust profitability margins through strategic operational adjustments.
Business Overview
UTMD has a long and storied history, having been founded in 1978 and establishing itself as a trusted provider of innovative medical technologies. The company's product portfolio spans a diverse range of categories, including obstetrics, gynecology, electrosurgery, urology, neonatal, and blood pressure monitoring. UTMD's devices are recognized globally by clinicians in over 100 countries as the standard for achieving optimal long-term patient outcomes.The company's manufacturing and distribution footprint extends across the United States, Ireland, the United Kingdom, Canada, Australia, and New Zealand, allowing it to serve a broad international customer base. UTMD's vertically integrated business model, which encompasses in-house research and development, production, and global commercialization, has been a key competitive advantage.
Financial Performance
For the full year 2023, UTMD reported annual net income of $16,635,000 on revenues of $50,224,000, representing a net profit margin of 33.1%. The company's annual operating cash flow was $22,281,000, while free cash flow reached $21,642,000, underscoring its strong liquidity and cash generation capabilities.In the first half of 2024, UTMD faced a 14.4% decline in consolidated revenues to $21,740,000, compared to $25,386,000 in the same period of the prior year. This top-line contraction was primarily driven by significant reductions in sales to the company's largest OEM customer, PendoTECH, as well as lower shipments to UTMD's largest blood pressure monitoring distributor in China.
Despite the revenue challenges, UTMD maintained healthy profitability margins. Gross profit in the first half of 2024 was $13,018,000, representing a gross margin of 59.9%, compared to 61.4% in the prior-year period. Operating income declined 17.4% to $7,321,000, with an operating margin of 33.7%. Net income for the first half of 2024 was $7,409,000, a decrease of 11.9% from the same period in 2023, with a net profit margin of 34.1%.
Segmental Performance
UTMD's revenue performance was mixed across its geographic and product segments. Domestic U.S. sales declined 15.3% to $12,023,000 in the first half of 2024, while international (OUS) sales decreased 13.1% to $9,718,000. The company's largest revenue declines were seen in the blood pressure monitoring and accessories category, which fell 57.5% due to the loss of the PendoTECH OEM business, as well as a 20.7% decline in shipments to the company's largest Chinese distributor.Conversely, UTMD's obstetrics and gynecology/electrosurgery/urology product categories demonstrated more resilient performance, with declines of 14.2% and 8.8%, respectively, in the first half of 2024 compared to the prior-year period.
Liquidity and Balance Sheet
UTMD maintains a strong balance sheet, with no debt and ample liquidity. As of June 30, 2024, the company had $89,219,000 in cash and investments, down slightly from $92,868,000 at the end of 2023. The current ratio stood at a robust 26.0, providing the company with the financial flexibility to navigate the current challenges.During the first half of 2024, UTMD repurchased 138,215 shares of its common stock for a total of $9,393,466, at an average price of $67.96 per share. The company also paid $2,170,000 in dividends to shareholders, underscoring its commitment to returning capital to investors.
Outlook and Risks
Looking ahead, UTMD expects the revenue declines experienced in the first half of 2024 to continue throughout the remainder of the year. The company projects a further $6 million reduction in sales to its former OEM customer, PendoTECH, as that customer has moved its sensor manufacturing in-house. Additionally, the company's largest Chinese distributor has postponed its fourth-quarter 2024 shipments, which were $1.2 million in the prior-year period.Despite these headwinds, UTMD remains focused on executing its strategic priorities, which include introducing new products, leveraging its global manufacturing and distribution capabilities, and defending the safety and effectiveness of its Filshie Clip System in the U.S. market. The company also continues to explore potential acquisition opportunities that could augment its revenue and earnings growth.
Risks facing UTMD include ongoing product liability litigation related to the Filshie Clip System, potential regulatory changes, and the inherent challenges of operating in a highly competitive medical device industry. The company's reliance on a limited number of large customers also presents concentration risk.